Enanta Pharmaceuticals (ENTA) Competitor Comparison
We are evaluating the key criteria listed to compare Enanta Pharmaceuticals (ENTA) against its competitors in the Biotechnology industry.
Market Capitalization
203 / 368Gross Profits
49 / 278Total Revenue
99 / 300EBITDA
238 / 337Free Cashflow
159 / 352Quick Ratio
144 / 357Earnings per Share
305 / 359Dividend yield
0 / 6Total Cash
84 / 358Performance 3 years
307 / 368Performance 5 years
268 / 368Performance 10 years
218 / 368Linearity 3 years
229 / 368Linearity 5 years
188 / 368Linearity 10 years
116 / 367Total Rank
115 / 368Dividend Rank
118 / 368Valuation Rank
256 / 368Piotroski Rank
230 / 368Muliplier Rank
49 / 368Market Capitalization - ENTA ranking 203 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.